Acurx pharmaceuticals, inc. announces closing of initial public offering of common stock and full exercise of underwriters' option to purchase additional shares

Staten island, n.y., june 29, 2021 /prnewswire/ -- acurx pharmaceuticals, inc. (nasdaq: acxp) (the "company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today the closing of its previously announced underwritten initial public offering of 2,875,000 newly-issued shares of common stock, including the full exercise by the underwriters of their option to purchase 375,000 additional shares of common stock, at a price to the public of $6.00 per share.
ACXP Ratings Summary
ACXP Quant Ranking